Ceftobiprole - Basilea Pharmaceutica
Alternative Names: BAL 9141-000; BAL9141; Ro-63-9141Latest Information Update: 11 Mar 2025
At a glance
- Originator Basilea Pharmaceutica; Roche
- Class Anti-infectives; Antibacterials; Cephalosporins; Skin disorder therapies; Small molecules
- Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Methicillin-resistant Staphylococcus aureus infections
- Discontinued Nosocomial infections
Most Recent Events
- 25 Feb 2025 Basilea Pharmaceutica completes a phase I trial (In volunteers) in Netherlands (IV) (NCT06808646)
- 17 Jan 2025 Phase-I clinical trials in Methicillin resistant Staphylococcus aureus infections (In volunteers) in Netherlands (IV) (NCT06808646)
- 27 Apr 2024 Antimicrobial data from a phase-III ERADICATE trial in Methicillin-resistant Staphylococcus aureus infection presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ECCMID 2024)